Literature DB >> 27377192

Safety, complications and patients' acceptance of Mohs micrographic surgery under local anaesthesia: results from the U.K. MAPS (Mohs Acceptance and Patient Safety) Collaboration Group.

W Hussain1, A Affleck2, F Al-Niaimi3, A Cooper4, E Craythorne3, C Fleming2, V Ghura5, J Langtry6, C Lawrence6, S Loghdey7, L Naysmith8, T Oliphant6, R Rahim6, S Rice6, M Sivaramkrishan2, G Stables1, S Varma7, R Mallipeddi3.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 27377192     DOI： 10.1111/bjd.14843

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  5 in total

1.  Process of Post-operative Telephone Follow-up Implementation for Mohs Micrographic Surgery: A Pilot Study.

Authors:  Brayden Forbes; Aaron M Secrest; Matthew Q Hand; Mark J Eliason
Journal:  J Clin Aesthet Dermatol       Date:  2018-07-01

2.  Lines under the eyes: a large prospective case series of linear basal cell carcinomas.

Authors:  D Rutkowski; N J Collier; N Telfer; V Ghura
Journal:  Arch Dermatol Res       Date:  2022-08-12       Impact factor: 3.033

Review 3.  Management of keratinocyte carcinoma - Special considerations in the elderly.

Authors:  Alison Bailey; Brooke Vasicek; Joy Tao; Monica Janeczek; Andia Mitri; Rebecca Tung
Journal:  Int J Womens Dermatol       Date:  2019-05-18

4.  Prevalence of wound complications following Mohs micrographic surgery (MMS): a cross-sectional study of 1000 patients undergoing MMS and wound repair in a UK teaching hospital.

Authors:  David Rutkowski; Zoe Littlewood; Sarah Judith Jean Touyz; Nicholas James Collier; Vishal Madan; Harvinder Singh Ghura; Zenas Zee Ngai Yiu; Nicholas Telfer
Journal:  Clin Exp Dermatol       Date:  2022-05-25       Impact factor: 4.481

5.  Mohs Micrographic Surgery for Primary Versus Recurrent or Incompletely Excised Facial High-risk Basal Cell Carcinomas.

Authors:  Hannah Ceder; Malin Grönberg; John Paoli
Journal:  Acta Derm Venereol       Date:  2021-02-02       Impact factor: 3.875
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.